Disclosure of Relevant Financial Relationships with Commercial Interests

USF Health endorses the standards of the ACCME and all applicable accrediting organizations that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Author

Editors in Chief

Staff

USF Health OCPD staff members and the peer/content reviewers for this activity have no relevant financial relationships to disclose. Disclosures are on file at the USF Health Office of Continuing Professional Development.

Additional Disclosure Information

The following staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tobira, and Tibotec; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.

Paul E. Sax, MD, disclosed that he had received consulting fees from Abbott, Aileron, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Pfizer, and ViiV and funds for research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Tibotec/Janssen at the time he contributed to this module.

Michael A. Craig, MSc; John McGuire, PhD; Elaine P. Seeskin; Kristen Rosenthal, PhD; and Lindsay Edwards, PhD, had nothing to disclose with regard to commercial interests at the time they contributed to this module.

Kimberly Y. Smith, MD, MPH, had disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.

Lynda Szczech, MD, MSCE, FASN, had disclosed that she had received fees for non-CME/CE services from Merck; received funds for research support from Amgen, Genzyme, Gilead Sciences, GlaxoSmithKline, Innocoll, Lultpold, Pfizer, and Roche Diagnostics; served as a consultant to Abbott, Amgen, AstraZeneca, Baxter, Gilead Sciences, Kuhura, Merck, and Roche Diagnostics; served on the advisory board for Gilead Sciences; and participated in a speaker bureau for Bristol-Myers Squibb, Gilead Sciences, and ViiV at the time she contributed to this module.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Unapproved Use Disclosure

USF Health requires CME faculty to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

USF Health Privacy Policy

USF Health Office of Continuing Professional Development (OCPD) has created a privacy policy to demonstrate our commitment to guarding the privacy of our clients. The following statements disclose our practices on gathering and disseminating information for this web site. The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual’s contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

If you have any questions about this privacy policy, please contact USF Health OCPD, at cpdsupport@health.usf.edu.

Equal Opportunity

USF is an Equal Opportunity/ Equal Access/ Affirmative Action Institution.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries, please contact: cpdsupport@health.usf.edu.

inPractice Hepatology current certification period
Release Date: January 1, 2019
Expiration Date: June 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with viral hepatitis.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

• Epidemiology and prevention: Evaluate current demographic trends in viral hepatitis, modes of sexual and nonsexual transmission of viral hepatitis, and guidelines for implementing viral hepatitis testing, prevention, and infection control
• Basic science: Interpret the clinical significance of natural history, disease pathogenesis, and factors associated with disease progression in patients with viral hepatitis
• Clinical management: Integrate appropriate methods of detection and diagnosis, patient history taking, syndromic evaluation for differential diagnosis, and health maintenance interventions into patient care in individuals with viral hepatitis; appraise the importance of diverse aspects of patient care including issues in specific patient populations and coordination of care
• Initial therapy for hepatitis B: Formulate state-of-the-art antiviral management strategies for treatment-naive patients with hepatitis B, including attention to considerations when selecting regimens, monitoring, and goals of therapy
• Initial therapy for hepatitis C: Apply state-of-the-art antiviral management strategies for treatment-naive patients with hepatitis C, including attention to considerations when selecting regimens, monitoring, goals of therapy, and use of response-guided treatment strategies
• Treatment-experienced hepatitis C patients: Optimally manage treatment-experienced patients, including setting appropriate goals of therapy, optimizing patient adherence, minimizing adverse events, and selecting optimal therapy, including dose and duration
• Antiviral resistance in hepatitis B: Mitigate the clinical impact of antiviral resistance, including resistance assays and their interpretation, patterns of emergent drug resistance associated with different regimens, and management of patients with resistance

Commercial Support

This program is supported by educational grants from AbbVie and Gilead Sciences.

inPractice HIV current certification period
Release Date: November 1, 2018
Expiration Date: April 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

• Demonstrate an improvement in patient outcomes by applying information at the point of care
• Epidemiology and prevention: evaluate current demographic trends in HIV disease, modes of sexual and nonsexual transmission of HIV, and Centers for Disease Control and Prevention guidelines for implementing HIV testing, prevention, and infection control
• HIV-related basic science: Interpret the clinical significance of the HIV life cycle and natural history, virologic and immunologic aspects of disease pathogenesis, and factors associated with disease progression
• Clinical management: Integrate methods of HIV detection and diagnosis, patient history taking, syndromic evaluation for differential diagnosis, and health maintenance interventions into patient care; apply best practices in diverse aspects of patient care including issues in specific patient populations and coordination of care
• Disease manifestations: Manage the clinical presentation, diagnosis, treatment, and prophylaxis for the full range of opportunistic diseases, coinfections, and HIV-associated disorders that may occur in HIV-infected patients
• Initial antiretroviral therapy: Formulate state-of-the-art antiretroviral management strategies for treatment-naive patients, including attention to considerations when selecting regimens, monitoring and goals of therapy, and strategies for maximizing adherence
• Antiretroviral resistance: Appraise the clinical impact of antiretroviral resistance, including resistance assays and their interpretation, transmitted resistance, and patterns of emergent drug resistance associated with different regimens
• Treatment-experienced patients: Optimally manage treatment-experienced patients, including setting appropriate goals of therapy and selecting active agents when constructing new regimens
• Complications of antiretroviral therapy: Manage common antiretroviral toxicities and drug-drug interactions among antiretroviral agents and among antiretrovirals and concomitant agents

Commercial Support:

This program is supported by educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV.

Physician Continuing Medical Education (for Point of Care CME activities)